All data are based on the daily closing price as of September 6, 2024
h
Handa Pharmaceuticals
6620.TWO
2.58 USD
0.01
+0.39%
Overview
Last close
2.58 usd
Market cap
364.14M usd
52 week high
6.30 usd
52 week low
2.15 usd
Target price
N/A usd
Valuation
P/E
25.8805
Forward P/E
N/A
Price/Sales
11.9342
Price/Book Value
3.9828
Enterprise Value
282.89M usd
EV/Revenue
9.3128
EV/EBITDA
15.1629
Key financials
Revenue TTM
30.38M usd
Gross Profit TTM
N/A usd
EBITDA TTM
16.53M usd
Earnings per Share
0.1 usd
Dividend
0.03 usd
Total assets
N/A usd
Net debt
N/A usd
About
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products. In addition, the company develops HND-004, a diabetic drug; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.